公司
公司
第 9847 位，共 75986 个前 13%本周下降 2136 位
3 条直接关系
所在群组共 1534 个紧密关联的对象，核心是
按有证据的公开关系计算，每天更新。
箭头表示关系方向，可按业务类别筛选。
Akeso has out-licensed the exclusive rights to develop and commercialize ivonescimab in the United States and Canada, South America, Europe, the Middle East, Africa, and Japan to Summit Therapeutics under an agreement查看来源
10 of which are being or have been conducted in China by Akeso查看来源
the impact of pharmaceutical industry regulation and health care legislation in the P.R. China, the United States and internationally查看来源
dependence on the effectiveness of Akeso's patents and other protections for innovative products查看来源
显示第 1 至 4 条，共 4 条
结合来源阅读结论，展开条目查看证据。
dependence on the effectiveness of Akeso's patents and other protections for innovative products
PR Newswire news releases · 2026-10-25 23:31
dependence on the effectiveness of Akeso's patents and other protections for innovative products查看来源
the impact of pharmaceutical industry regulation and health care legislation in the P.R. China, the United States and internationally
PR Newswire news releases · 2026-10-25 23:31
the impact of pharmaceutical industry regulation and health care legislation in the P.R. China, the United States and internationally查看来源
Eight innovative drugs are commercially available, and two additional drugs with three indications are currently under regulatory review for marketing approval.
PR Newswire news releases · 2026-10-25 23:31
Eight innovative drugs are commercially available, and two additional drugs with three indications are currently under regulatory review for marketing approval.查看来源
Eight innovative drugs are commercially available, and two additional drugs with three indications are currently under regulatory review for marketing approval.
PR Newswire news releases · 2026-10-25 23:31
Eight innovative drugs are commercially available, and two additional drugs with three indications are currently under regulatory review for marketing approval.查看来源
Of these, nearly 30 candidates have advanced into clinical trials, including 15 bispecific or multi-specific antibodies and bispecific ADCs.
PR Newswire news releases · 2026-10-25 23:31
Of these, nearly 30 candidates have advanced into clinical trials, including 15 bispecific or multi-specific antibodies and bispecific ADCs.查看来源
Eight innovative drugs are commercially available, and two additional drugs with three indications are currently under regulatory review for marketing approval.
PR Newswire news releases · 2026-10-25 23:31
Eight innovative drugs are commercially available, and two additional drugs with three indications are currently under regulatory review for marketing approval.查看来源
显示第 1 至 6 条，共 16 条
估值数据需要 Pro 或 Research。
升级到 Pro 解锁这家公司有哪些页面值得盯着，比如价格、更新日志、条款或招聘页？推荐给我们。每条推荐都有人看；收录后，这个页面会为所有读者一起监测，并且只有连续两次抓取一致才算一次变化。
暂无: 公司信号 · 财务数据 · 披露文件 · 据点 · 业绩指引